Let's see what's new in the market
Air Techniques International Adds New European Standard for Respiratory Protective Devices to its 100X Automated Filter Tester
Air Techniques International (ATI), a global leader in the design and manufacture of specialized testing equipment for HEPA filters, media, filter cartridges, respirators, and protective masks, announced today the addition of European Standard EN 13274-7:2019 for Paraffin Oil to its 100X Automated Filter Tester lineup. The 100X automated filter tester with full EN13274-7:2019 compliance has already been delivered to leading filter manufacturers from ATI’s global Headquarters in Owings Mills, MD, USA. EN 13274-7:2019 supersedes the previous standard (EN 13274-7:2008) and acts as the test method to determine particle filter penetration for respiratory protective devices. EN 13274-7 standard is the test method called by EN 149 for the testing of filtering half masks to protect against particles (FFP1, FFP2 & FFP3 masks) which are in high demand during the current global Covid-19 pandemic.
Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer
Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher'snext-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be eligible for Enhertu, a HER2 directed antibody drug conjugate (ADC), which is currently in global phase 2 development for HER2 mutated or HER2 overexpressing NSCLC. Enhertu has demonstrated a strong response rate in patients with HER2 positive metastatic breast cancer and preliminary results show a similar response in patients with metastatic NSCLC with HER2 mutations.1-2 HER2 mutations have long been implicated in breast cancers, but they are considered a rare event in NSCLC. Recent studies have found that HER2 mutations are the key drivers in about 1-3 percent of NSCLC cases.Under the terms of the agreement, Thermo Fisher will retain rights to commercialize the test globally and will seek approval from regulatory agencies. The announcement follows a 2018 agreement between the companies to expand the clinical utility of the test in support of clinical trials and drug development programs at Daiichi Sankyo.
SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration (FDA) for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox pandemic or outbreak. While vaccines would play an important role in containing the spread of smallpox, they are only effective if administered prior to infection or no later than four days after infection. However, symptoms of smallpox do not typically appear until approximately 14 days post-infection, and there is currently no diagnostic test to determine infection prior to symptom onset. Given the uncertainty of an individual’s infection status in that two-week period, and the highly contagious nature of smallpox, the administration of a vaccine in combination with TPOXX could be an important strategy for reducing morbidity and mortality in a smallpox outbreak.
DKSH and Bruker have extended their distribution agreement in China to expand coverage for Bruker’s 3D X-ray Microscopy product portfolio for non-destructive imaging technology.
DKSH Business Unit Technology and Bruker, renowned for its market leading analytical X-ray solutions, have extended their distribution agreement in China. Last year in April, the two companies strengthened their partnership in Asia by adding a business cooperation in China with the distribution of the Bruker XRF products S2 PUMA and S2 POLAR. With the extended agreement, DKSH will also provide marketing, sales and after-sales services in China for the Bruker 3D X-ray Microscopy product line. The 3D X-ray Microscopy product portfolio consist of three powerful benchtop systems and the SKYSCAN 2214, which is the highest resolution 3D X-ray microscope launched by Bruker, a pioneer in X-ray nano-tomography. The entire SKYSCAN series offers 3D X-ray microscopy at exceptional resolution with an unparalleled user experience. DKSH aims to bring 3D X-ray Microscopy to customers across a range of material science industries, including geology, oil & gas exploration, polymers & composites, batteries & energy storage, pharma & packaging, automotive & aerospace, 3D printing and electronics.